Expanded targeting scope of LbCas12a variants allows editing of multiple oncogenic mutations.

Choi, Eunyoung; Hwang, Hye-Yeon; Kwon, Eunji; Kim, Daesik; Koo, Taeyoung

Choi, Eunyoung; Hwang, Hye-Yeon; Kwon, Eunji; Kim, Daesik; Koo, Taeyoung.

Afiliação

Choi E; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
Hwang HY; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea.
Kwon E; Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
Kim D; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon 16419, Republic of Korea.
Koo T; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.

Mol Ther Nucleic Acids ; 30: 131-142, 2022 Dec 13.

Article em En | MEDLINE | ID: mdl-36250202

Palavras-chave

CRC; CRISPR; LbABE8e; LbCas12a; MT: RNA/DNA editing; base editing; colorectal cancer; gene therapy; non-canonical PAMs; oncogenic mutation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Nucleic Acids Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google